Nuvation Bio Inc (NUVB) - Total Assets
Based on the latest financial reports, Nuvation Bio Inc (NUVB) holds total assets worth $744.50 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nuvation Bio Inc - Total Assets Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see Nuvation Bio Inc (NUVB) market capitalisation for the company's overall valuation and market capitalisation.
Nuvation Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Nuvation Bio Inc's total assets of $744.50 Million consist of 96.1% current assets and 3.9% non-current assets. Review how much debt does Nuvation Bio Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.6% |
| Accounts Receivable | $19.36 Million | 3.3% |
| Inventory | $11.41 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.21 Million | 1.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NUVB stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuvation Bio Inc's current assets represent 96.1% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2025, down from 87.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 3.3% of total assets.
Nuvation Bio Inc Competitors by Total Assets
Key competitors of Nuvation Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $511.25 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Nuvation Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.37 | 9.39 | 59.86 |
| Quick Ratio | 8.14 | 9.38 | 59.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $639.68 Million | $556.85 Million | $783.30 Million |
Nuvation Bio Inc - Advanced Valuation Insights
This section examines the relationship between Nuvation Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.13 |
| Latest Market Cap to Assets Ratio | 3.44 |
| Asset Growth Rate (YoY) | 10.0% |
| Total Assets | $594.82 Million |
| Market Capitalization | $2.05 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nuvation Bio Inc's assets at a significant premium (3.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Nuvation Bio Inc's assets grew by 10.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nuvation Bio Inc (2018–2025)
The table below shows the annual total assets of Nuvation Bio Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $594.82 Million | +10.02% |
| 2024-12-31 | $540.63 Million | -13.01% |
| 2023-12-31 | $621.48 Million | -7.54% |
| 2022-12-31 | $672.14 Million | -13.40% |
| 2021-12-31 | $776.15 Million | +249.95% |
| 2020-12-31 | $221.79 Million | +83.37% |
| 2019-12-31 | $120.95 Million | +76451.90% |
| 2018-12-31 | $158.00K | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more